Article info
Editorial commentary
Plasma microRNA signature as biomarker for disease progression in frontotemporal dementia and amyotrophic lateral sclerosis
- Correspondence to Dr Bryan J Traynor, Laboratory of Neurogenetics (NIA/NIH), National Institutes of Health, Bethesda, Maryland 20892-3707, USA; traynorb{at}mail.nih.gov
Citation
Plasma microRNA signature as biomarker for disease progression in frontotemporal dementia and amyotrophic lateral sclerosis
Publication history
- Received January 27, 2021
- Revised February 16, 2021
- Accepted February 18, 2021
- First published March 15, 2021.
Online issue publication
January 16, 2022
Article Versions
- Previous version (16 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.